Vital Farms remains a Buy despite a 30% stock decline, as fundamentals and growth prospects remain strong. VITL reported accelerating revenue growth, margin expansion, and consistent earnings beats, ...
Genpact is executing a successful pivot toward higher-value technology and AI-led services, reinforcing my Buy rating with increased conviction. ATS revenue grew 17% to $1.2B in FY2025, now 24% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results